NCT01111656 - Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Relapsing-remitting Multiple Sclerosis

Interventions

DRUG

Interferon beta-1b group

Patients receive interferon beta-1b 250ug subcutaneously every other day

DRUG

Interferon beta-1b/Atorvastatin group

Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)

Trial Locations (1)

Department of Neurology, Bern University Hospital, and University of Bern, Bern